Pfizer’s palbociclib Phase 2 trial achieves primary endpoint in patients with advance

[News]

Pfizer Inc. today announced that the randomized Phase 2 trial [PALOMA-1] of palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for the combination of palbociclib and letrozole compared with letrozole alone in post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or newly diagnosed metastatic breast cancer.

More... (http://www.news-medical.net/news/20140204/Pfizere28099s-palbociclib-Phase-2-trial-achieves-primary-endpoint-in-patients-with-advanced-breast-cancer.aspx)